Some awesome classic cars will be rumbling through downtown Fort Worth this weekend as the annual Cowtown Cruisin’ For a Cure event rolls into North Texas.
The results of a long-term major federal study that was done in Texas is easing worries about the safety of a hormone-blocking drug that can lower a man’s chances of developing prostate cancer.
A new study shows how important it is for men to carefully consider treatments for early-stage prostate cancer. Fifteen years after surgery or radiation treatment, nearly all of the older men in the study had some problems having sex.
The Food and Drug Administration has expanded approval of Johnson & Johnson’s prostate cancer pill Zytiga for men with an earlier stage of the disease.
A drug that is commonly used to treat men with enlarged prostates may also delay the growth of prostate cancer, according to a new study.
Doctors say men can experience their own version of hormonal change which some are calling “man-opause” or more accurately Andropause.
No major medical group recommends routine PSA blood tests to check men for prostate cancer, and now a government panel is saying they do more harm than good.
A rising PSA level isn’t such a good predictor of prostate cancer after all and can lead to many unnecessary biopsies, says a large new study.
A new experimental test may someday help doctors with one of the most vexing problems in cancer therapy: identifying which prostate cancer patients need aggressive treatment.